Praluent

Lowering Cholesterol

Praluent is primarily used to treat adults with primary hyperlipidemia, a condition characterized by high levels of low-density lipoprotein (LDL) cholesterol, often called "bad" cholesterol. It is typically prescribed when diet and other medications, such as statins, have not sufficiently lowered cholesterol levels.

Inherited Cholesterol Conditions

This medication is also used for individuals with genetic conditions that cause dangerously high cholesterol levels, including:

• Heterozygous familial hypercholesterolemia (HeFH): An inherited condition that causes high LDL cholesterol.
• Homozygous familial hypercholesterolemia (HoFH): A rare and more severe inherited condition that causes extremely high LDL cholesterol levels. For HoFH, Praluent is used in combination with other cholesterol-lowering treatments.

Reducing Cardiovascular Risk

In adults who already have established heart or blood vessel disease, Praluent is used to lower the risk of:

• Heart attack (myocardial infarction).
• Stroke.
• Unstable angina (chest pain) that requires hospitalization.

Mechanism of Action

Praluent belongs to a class of drugs known as PCSK9 inhibitors. It works by targeting and blocking a protein in the liver called proprotein convertase subtilisin/kexin type 9 (PCSK9).

To understand how Praluent works, it is helpful to look at how the body naturally manages cholesterol:

• LDL Receptors: The liver has receptors on its surface that act like magnets to pull LDL (bad) cholesterol out of the bloodstream so it can be broken down and removed from the body.
• The Role of PCSK9: The PCSK9 protein normally binds to these LDL receptors and causes them to be broken down. When these receptors are destroyed, the liver cannot remove as much cholesterol, leading to higher levels of LDL in the blood.

Praluent attaches to the PCSK9 protein and prevents it from binding to the LDL receptors. By blocking this protein, the medication allows more receptors to remain active on the surface of the liver. These additional receptors can then capture and clear more LDL cholesterol from the blood, which lowers the overall level of circulating cholesterol.

Common Side Effects

Many people using Praluent experience mild side effects. These may include:

• Redness, itching, swelling, or pain at the injection site
• Cold symptoms, such as a sore throat, sneezing, or a runny nose
• Flu-like symptoms
• Muscle aches or pain
• Cough
• Diarrhea
• Urinary tract infection

Serious Side Effects

Contact a healthcare provider immediately or seek emergency medical care if you experience symptoms of a serious allergic reaction, such as:

• Severe rash, hives, or intense itching
• Swelling of the face, lips, tongue, or throat
• Trouble breathing or swallowing
• Signs of vasculitis, which may include purple spots on the skin, fever, or a general feeling of being unwell

Allergic Reactions

Serious hypersensitivity reactions, including some requiring hospitalization, have been reported with the use of this medication. Symptoms may include severe rash, itching, or hives. If a serious allergic reaction occurs, treatment is typically discontinued and medical care is provided to manage the symptoms.

Contraindications

This medication is contraindicated in patients who have a history of a serious hypersensitivity reaction to alirocumab or any of the inactive ingredients in the injection.

Pregnancy and Breastfeeding

There is limited information regarding the safety of using this medication during pregnancy. As a monoclonal antibody, it is likely to be transported across the placenta and may affect the developing fetus. It is also unknown if the drug passes into human breast milk. Healthcare providers typically weigh the potential benefits against the risks when considering treatment for individuals who are pregnant or nursing.

Other Precautions

• Kidney and Liver Function: While dose adjustments are generally not required for mild to moderate kidney or liver issues, there is limited data on the effects of this medication in people with severe impairment in these organs.
• Pediatric Use: The safety and effectiveness of this medication have not been established in all pediatric populations, though it is used for specific genetic conditions in children aged 8 years and older.

Pregnancy

There is limited information available regarding the safety of Praluent use during pregnancy. While animal studies did not indicate direct harm to the fetus, monoclonal antibodies such as Praluent are known to cross the placenta, particularly during the second and third trimesters. The potential risk to a human fetus is not fully understood.

If you are pregnant or planning to become pregnant, discuss the risks and benefits of this medication with your healthcare provider. They will determine if the treatment is appropriate for your specific medical needs during pregnancy.

Breastfeeding

It is not known if Praluent passes into human breast milk or if it could affect a breastfeeding child. Because many drugs are present in human milk, healthcare providers typically advise caution.

If you are breastfeeding or planning to breastfeed, talk to your doctor. You will need to weigh the benefits of the medication for your health against the potential risks to your nursing infant.

Available Forms

Praluent is supplied as a sterile, preservative-free liquid solution. It is available in the following delivery formats:

• Single-dose pre-filled pen: A disposable device designed for self-administration.
• Single-dose pre-filled syringe: A disposable syringe containing a fixed dose of the medication.

The solution is typically clear and colorless to pale yellow. These forms are intended for subcutaneous injection only, meaning they are injected into the fatty tissue just beneath the skin.

FDA Approval and Indications

Praluent (alirocumab) received its initial approval from the U.S. Food and Drug Administration (FDA) in 2015. It belongs to a class of drugs known as PCSK9 inhibitors.

The FDA has approved Praluent for the following indications in adults:

• To reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
• To be used in combination with diet, either alone or with other lipid-lowering therapies, for the treatment of primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL) cholesterol.
• To reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia.

Safety and Monitoring

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for this medication. Regulatory approval was based on clinical evidence showing the drug's ability to significantly lower LDL cholesterol levels and reduce the incidence of major adverse cardiovascular events when used as directed.

Factors Influencing Cost

The price of Praluent can vary based on several factors, including your specific insurance plan, the pharmacy you visit, and whether you qualify for cost-saving programs.

Generic and Biosimilar Status

Praluent is a brand-name medication and is not currently available in a generic or biosimilar form. Biologic drugs like Praluent are often more expensive than traditional medications because of the complex manufacturing processes required.

Insurance and Prior Authorization

Insurance companies often require prior authorization before they will cover Praluent. This means your healthcare provider must submit a request to your insurance company to prove that the medication is medically necessary for your condition.

Financial Assistance Programs

Financial assistance may be available through the manufacturer for eligible patients. This can include copay cards for those with commercial insurance or patient assistance programs for individuals who are uninsured or have limited coverage.